AEMD AEMD
Company Profile ↓Company Overview
AEMD (AEMD) is a publicly traded company listed on with a market capitalization of $1.02M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -73.14% |
| 6 Months: | +39.48% |
| 3 Months: | +37.71% |
| 1 Month: | +345.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)81.33 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 94.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 81 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Jun 2014 | Sep 2014 | Dec 2014 | Jun 2015 | Sep 2015 | Dec 2015 | Jun 2016 | Sep 2016 | Dec 2016 | Jun 2017 | Sep 2017 | Dec 2017 | Jun 2018 | Sep 2018 | Dec 2018 | Jun 2019 | Sep 2019 | Dec 2019 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.97K | 131.97K | 17.12K | 0 | 0 | 0 | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00M | 1.79M | 1.51M | 2.06M | 1.93M |
| Operating Income | -229.80K | -1.23M | -1.17M | -601.19K | -1.09M | -1.09M | -1.12M | -1.08M | -1.13M | -2.23M | -1.24M | -1.16M | -1.24M | -1.16M | -1.10M | -1.35M | -1.96M | -1.57M | -1.70M | -876.41K | -1.41M | -1.77M | -2.44M | -2.10M | -2.01M | -2.53M | -2.91M | -3.67M | -2.85M | -3.41M | -3.18M | -3.57M | -2.62M | -2.90M | - | -2.00M | -1.79M | -1.51M | -2.06M | -1.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.96M | -1.71M | -1.43M | -1.98M | -1.69M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.25M | -1.76M | -1.49M | -2.02M | -1.88M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.35M | -2.23M | -3.66M | -847.41K | -1.55M | -1.18M | -1.22M | -1.22M | -2.13M | -2.26M | -1.21M | -1.84M | -1.30M | -1.22M | -1.15M | -1.39M | -2.01M | -2.07M | -1.71M | -819.58K | -1.41M | -1.77M | -2.44M | -2.10M | -2.01M | -2.53M | -2.91M | -3.81M | -2.85M | -3.28M | -3.03M | -3.47M | -2.57M | -2.81M | - | -6.25M | -1.76M | -1.49M | -2.02M | -1.88M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.16 | -0.13 | -0.16 | -0.19 | -1.84 | -1.24 | -1.35 | -1.22 | -1.37 | -2.76 | -16.11 | -50.25 | - | -42.50 | -187.00 | -12.25 | - |
| R&D Expense | 293.58K | 542.38K | 347.00K | 250.39K | 214.16K | 182.00K | 207.68K | 147.80K | 117.66K | 333.43K | 178.44K | 157.46K | 168.57K | 129.21K | 194.78K | 178.80K | 243.84K | 248.87K | 222.86K | 218.57K | 377.17K | 508.90K | 461.18K | 587.69K | 478.20K | 354.57K | 858.35K | 852.46K | 558.22K | 678.92K | 628.45K | 593.40K | 414.66K | 261.49K | 240.20K | - | 524.37K | 294.32K | 532.78K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.36M | 1.23M | 1.62M | 762.42K | 886.57K | 392.07K | 149.62K | 229.62K | 650.19K | 659.10K | - | 574.25K | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 12.47M | 12.64M | 9.34M | 7.29M |
| Operating Income | -4.56M | -3.11M | -3.58M | -3.06M | -3.99M | -4.38M | -6.10M | -4.83M | -6.00M | -5.93M | -7.89M | - | -11.90M | -12.64M | -9.34M | -7.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -11.66M | -12.28M | -13.04M | -6.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.11K | 14.37K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -12.03M | -12.21M | -13.39M | -7.15M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.71M | -8.11M | -4.89M | -13.36M | -6.80M | -4.87M | -7.28M | -5.68M | -6.19M | -6.37M | -7.89M | - | -12.03M | -12.21M | -13.39M | -7.15M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -2,360.00 | -1,944.00 | -428.85 | -10.61 |
| R&D Expense | - | - | 1.44M | 1.51M | 1.03M | 782.00K | 673.00K | 586.00K | 896.00K | 927.00K | 2.07M | 2.34M | 2.75M | 2.52M | 2.21M | 1.91M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 567.22K | 838.69K | 496.69K | 1.70M | 1.38M | 2.53M | 1.73M | 7.35M | 4.12M | 10.39M | 10.67M | - | 17.51M | 8.25M | 7.36M | 6.33M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.09M | 6.23M | 5.95M | 5.57M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | 9.60M | 9.86M | - | 14.53M | 5.44M | 5.50M | 5.03M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 127.97K | 0 | - | - | - |
| Total Liabilities | - | - | - | 9.64M | 16.43M | 729.21K | 1.03M | 1.13M | 1.32M | 1.82M | 1.11M | 1.38M | - | 2.44M | 2.48M | 2.24M | 1.45M |
| Current Liabilities | - | 6.54M | 10.13M | 9.64M | 15.65M | 573.98K | 526.61K | 611.76K | 477.96K | 1.82M | 1.07M | 1.38M | - | 1.51M | 1.83M | 1.90M | 1.45M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21M | 940.32K | 649.75K | 336.72K |
| Total Equity | -4.40M | -5.98M | -9.30M | -9.14M | -14.95M | 615.45K | 1.55M | 676.38K | 6.13M | 2.43M | 9.41M | 9.43M | - | 15.06M | 5.77M | 5.12M | 4.89M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.75K | 6.57K | 51.70K | 314.09K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.97M | -1.84M | -2.10M | -2.14M | -5.05M | -4.33M | -3.51M | -3.91M | -4.29M | -5.20M | -6.76M | - | -10.51M | -10.13M | -7.65M | -7.00M |
| Investing Cash Flow | -9.35K | -1.74K | 0 | -96.06K | 0 | -9.31K | -16.43K | -24.82K | 0 | -151.66K | -59.88K | - | -943.11K | -250.87K | 0 | -3.70K |
| Financing Cash Flow | 1.93M | 1.97M | 2.08M | 3.36M | 4.65M | 5.61M | 2.96M | 9.35M | 1.15M | 11.13M | 7.13M | - | 8.91M | 1.29M | 7.73M | 6.52M |
| Capital Expenditure | -2.54K | -1.74K | -0 | -96.06K | -0 | -9.31K | -16.43K | -24.82K | -0 | -151.66K | -59.88K | -349.19K | -943.11K | -250.87K | - | -3.70K |
| Free Cash Flow | -1.97M | -1.84M | -2.10M | -2.24M | -5.05M | -4.34M | -3.52M | -3.94M | -4.29M | -5.35M | -6.82M | - | -11.45M | -10.38M | -7.65M | -7.00M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -2.53M | -9.09M | 81.85K | -480.19K |
Ratios (Annual)
Figures in %.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -229.1% | -290.7% | -188.2% | -523.7% | -494.6% | -1,555.4% | -3,228.8% | -2,612.5% | -912.0% | -1,197.3% | - | -2,072.0% | - | - | - |
| Net Margin % | - | -596.6% | -397.7% | -822.6% | -891.5% | -549.6% | -1,855.8% | -3,795.9% | -2,697.8% | -980.3% | -1,196.6% | - | -2,094.9% | - | - | - |
| ROE % | 95.6% | 87.3% | 53.5% | 89.4% | -1,104.4% | -313.8% | -1,075.7% | -92.6% | -255.4% | -67.7% | -83.6% | - | -79.9% | -211.7% | -261.3% | -146.4% |
| ROCE % | 76.3% | 33.5% | 39.1% | 21.9% | -495.0% | -219.0% | -547.1% | -70.3% | -260.9% | -63.6% | -84.9% | - | -74.3% | -197.0% | -171.1% | -149.3% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AEMD
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter e…
Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
MIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companie…
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study d…
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its co…
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Jour…
Aethlon Medical advances Hemopurifier study as final trial cohort nears completion
Aethlon Medical CEO James Frakes joined Steve Darling from Proactive to discuss the company’s Hemopurifier® technology and the progress of its ongoing clinical program evaluating the device’s potential role in cancer treatment. The Hemopuri…
AEMD — Frequently Asked Questions
What is the current share price of AEMD?
As of 2026-08-05 17:25 PDT, AEMD trades at $3.25 on NASDAQ/NYSE. Its 52-week range is $0.53 to $60.00.
What is the market capitalisation of AEMD?
AEMD has a market capitalisation of $1.02M on NASDAQ/NYSE.
What is the P/E ratio of AEMD?
AEMD trades at a trailing price-to-earnings (P/E) ratio of -0.31. Its price-to-book (P/B) ratio is 0.21.
What is the return on equity (ROE) of AEMD?
AEMD has a return on equity (ROE) of -146.36%. Its return on capital employed (ROCE) is -149.27%.
Is AEMD a good stock to buy?
This page provides a data-driven analysis of AEMD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.